Sulphonylurea derivatives in the treatment of type 2 diabetes mellitus at current stage
The treatment algorithm of patients with type 2 diabetes mellitus (T2DM) is described; it emphasized that only sulfonylurea derivatives (SUD) are first-line therapy of type 2 diabetes in comparison with other antihyperglycemic medicines which decrease insulin secretion. Data for pharmacological properties and clinical efficacy of modern SUDs, particularly for glimepiride (Amarilla) - at current stage single agent by the 3rd generation of this antihyperglycemic drug class with several advantages are presented. Safety profile of SUD is discussed. It is stated that in case of initial treatment failure second compulsory component of treatment should be SUDs, with preference for more modern drugs, in agreement with Russian and the international recommendations for the treatment of type 2 diabetes

Keywords: glimepiride, sulfonylurea derivatives, hypoglycemic therapy, type 2 diabetes mellitus